168 related articles for article (PubMed ID: 16219965)
1. Clopidogrel-induced hepatotoxicity after percutaneous coronary stenting.
Chau TN; Yim KF; Mok NS; Chan WK; Leung VK; Leung MF; Lai ST
Hong Kong Med J; 2005 Oct; 11(5):414-6. PubMed ID: 16219965
[TBL] [Abstract][Full Text] [Related]
2. Fatal liver injury associated with clopidogrel.
Kastalli S; El Aïdli S; Zaïem A; ben Abdallah H; Daghfous R
Fundam Clin Pharmacol; 2010 Aug; 24(4):433-5. PubMed ID: 19895648
[TBL] [Abstract][Full Text] [Related]
3. Clopidogrel treatment in a patient with ticlopidine-induced hepatitis following percutaneous coronary stenting.
Anselmino M; Moretti C; Ravera L; Sheiban I
Minerva Cardioangiol; 2010 Apr; 58(2):277-80. PubMed ID: 20440256
[TBL] [Abstract][Full Text] [Related]
4. An idiosyncratic reaction to clopidogrel.
Kapila A; Chhabra L; Locke AD; Patel P; Khanna A; Reddy CM; Young MF
Perm J; 2015; 19(1):74-6. PubMed ID: 25663208
[TBL] [Abstract][Full Text] [Related]
5. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes.
Mitsios JV; Papathanasiou AI; Rodis FI; Elisaf M; Goudevenos JA; Tselepis AD
Circulation; 2004 Mar; 109(11):1335-8. PubMed ID: 15023882
[TBL] [Abstract][Full Text] [Related]
6. High on clopidogrel treatment platelet reactivity is frequent in acute and rare in elective stenting and can be functionally overcome by switch of therapy.
Leé S; Vargová K; Hizoh I; Horváth Z; Gulácsi-Bárdos P; Sztupinszki Z; Apró A; Kovács A; Préda I; Tóth-Zsámboki E; Kiss RG
Thromb Res; 2014 Feb; 133(2):257-64. PubMed ID: 24359966
[TBL] [Abstract][Full Text] [Related]
7. Clopidogrel use in coronary heart disease and percutaneous coronary intervention.
Atiemo AD; Williams MS
J Investig Med; 2008 Apr; 56(4):689-700. PubMed ID: 18382265
[TBL] [Abstract][Full Text] [Related]
8. Clopidogrel-induced hepatocellular injury and cholestatic jaundice in an elderly patient: case report and review of the literature.
Goyal RK; Srivastava D; Lessnau KD
Pharmacotherapy; 2009 May; 29(5):608-12. PubMed ID: 19397467
[TBL] [Abstract][Full Text] [Related]
9. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial.
von Beckerath N; Taubert D; Pogatsa-Murray G; Schömig E; Kastrati A; Schömig A
Circulation; 2005 Nov; 112(19):2946-50. PubMed ID: 16260639
[TBL] [Abstract][Full Text] [Related]
10. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
Reaume KT; Regal RE; Dorsch MP
Ann Pharmacother; 2008 Apr; 42(4):550-7. PubMed ID: 18319394
[TBL] [Abstract][Full Text] [Related]
11. Clopidogrel-induced mixed hepatocellular and cholestatic liver injury.
Willens HJ
Am J Ther; 2000 Sep; 7(5):317-8. PubMed ID: 11317178
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of ischemic heart disease with the platelet aggregation inhibitor clopidogrel].
Helø OH; Madsen JK; Kastrup J
Ugeskr Laeger; 2004 Apr; 166(18):1659-62. PubMed ID: 15174400
[No Abstract] [Full Text] [Related]
13. Clinico-histopathological characteristics of clopidogrel-induced hepatic injury: case report and review of literature.
Höllmüller I; Stadlmann S; Graziadei I; Vogel W
Eur J Gastroenterol Hepatol; 2006 Aug; 18(8):931-4. PubMed ID: 16825915
[TBL] [Abstract][Full Text] [Related]
14. Thrombotic and bleeding events after coronary stenting according to clopidogrel and aspirin platelet reactivity: VerifyNow French Registry (VERIFRENCHY).
Rangé G; Yayehd K; Belle L; Thuaire C; Richard P; Cazaux P; Barbou F; Köning R; Chassaing S; Teiger E; Berthier R; Decomis MP; Claudel JP; Delarche N; Brunel P; De Poli F; Dupouy P; Beygui F; Albert F; Collet JP; Montalescot G;
Arch Cardiovasc Dis; 2014 Apr; 107(4):225-35. PubMed ID: 24794216
[TBL] [Abstract][Full Text] [Related]
15. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.
Cuisset T; Frere C; Quilici J; Morange PE; Mouret JP; Bali L; Moro PJ; Lambert M; Alessi MC; Bonnet JL
JACC Cardiovasc Interv; 2008 Dec; 1(6):649-53. PubMed ID: 19463379
[TBL] [Abstract][Full Text] [Related]
16. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?
Bliden KP; DiChiara J; Tantry US; Bassi AK; Chaganti SK; Gurbel PA
J Am Coll Cardiol; 2007 Feb; 49(6):657-66. PubMed ID: 17291930
[TBL] [Abstract][Full Text] [Related]
17. Clopidogrel-induced hepatotoxicity.
Wiper A; Schmitt M; Roberts DH
J Postgrad Med; 2008; 54(2):152. PubMed ID: 18480537
[No Abstract] [Full Text] [Related]
18. A randomized trial comparing clopidogrel versus ticlopidine therapy in patients undergoing infarct artery stenting for acute myocardial infarction with abciximab as adjunctive therapy.
Parodi G; Sciagrà R; Migliorini A; Memisha G; Moschi G; Valenti R; Pupi A; Antoniucci D
Am Heart J; 2005 Aug; 150(2):220. PubMed ID: 16086921
[TBL] [Abstract][Full Text] [Related]
19. Clopidogrel-induced hepatotoxicity and fever.
Ng JA; Goldberg N; Tafreshi MJ
Pharmacotherapy; 2006 Jul; 26(7):1023-6. PubMed ID: 16878371
[TBL] [Abstract][Full Text] [Related]
20. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Matetzky S; Shenkman B; Guetta V; Shechter M; Beinart R; Goldenberg I; Novikov I; Pres H; Savion N; Varon D; Hod H
Circulation; 2004 Jun; 109(25):3171-5. PubMed ID: 15184279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
